Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MPC-7869 (Flurizan) in Mild Alzheimer's Disease
NCT00322036Phase 3Terminated
- Sponsor
- Myrexis, Inc.
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing MPC-7869 with Placebo (2 arms). Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 18 months and Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory at 18 months. Started May 2006; status: terminated.
02
Drugs
tarenflurbil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00322036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322036.